Dublin, Dec. 30, 2019 (GLOBE NEWSWIRE) -- The "Biosimilars Market By Product, By Technology, By Indication, By Manufacturing Type, By Route of Administration, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024" report has been added to ResearchAndMarkets.com's offering.

The biosimilars market is predicted to reach $26.7 billion by 2024, progressing at a CAGR of 29.6% during the forecast period (2019-2024).

The market is driven by the rising prevalence of the chronic disease, growing investment in research and development by biopharmaceutical organizations, the vast pipeline of biosimilars, surging geriatric population, and the cost-efficient nature of biosimilars as compared to approved drugs.

On a global ground, in 2018, Europe dominated the biosimilars market with nearly 47.7% share. This is ascribed to the flexible regulatory parameters, surging aging population, and increasing R&D investments by biopharmaceutical organizations in the region.

The biosimilars market is expected to observe the fastest growth in North America, progressing at CAGR of 32.7% during the 2019-2024 period. This can be mainly attributed to the surging geriatric population, increasing prevalence of chronic diseases, and growth in R&D investments.

Companies in North America have more freedom to price their products as they want compared to other regions, and advanced technologies and trained scientific personnel are readily available in here, which make it ideal for pharmaceutical companies.

According to the Population Reference Bureau report, titled Aging in the United States, the aging population is anticipated to double by 2060, resulting in the need for old age-related disease management. Furthermore, according to the Centers for Disease Control and Prevention (CDC), around 60.0% of the adults in the U.S. are suffering from one or more chronic diseases.

Strategic collaborations and product launches play a prominent role in the growth of the biosimilars market. For instance, Amgen Inc. and Entera Bio Ltd. collaborated in 2018 to launch an orally administered formulation of biologics. This collaboration shows that organizations are ready to invest in biologics, resulting in the growth of the market.

Furthermore, in January 2019, Samsung Bioepis Co. Ltd. partnered with 3SBio Group to expand the business of biosimilars in China. With the collaboration, Samsung Bioepis Co. Ltd. will seek to enlarge its biosimilars portfolio, while 3SBio Group will be supported by the sales of Avastin.

Key Topics Covered:

Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Research Scope
1.3.1 Market Segmentation by Product
1.3.2 Market Segmentation by Technology
1.3.3 Market Segmentation by Indication
1.3.4 Market Segmentation by Manufacturing Type
1.3.5 Market Segmentation by Route of Administration (ROA)
1.3.6 Market Segmentation by Geography
1.3.7 Analysis Period
1.3.8 Market Data Reporting Unit
1.3.8.1 Value
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By region
2.2.1.2 By industry participant
2.2.1.3 By company type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Product
4.1.2 By Technology
4.1.3 By Indication
4.1.4 By Manufacturing Type
4.1.5 By ROA
4.2 Market Dynamics
4.3 Porter's Five Forces Analysis
4.4 Pricing Policies for Biosimilars
4.5 Pricing Scenario for Biosimilars
4.6 Positive Attributes for Biosimilar Pricing

Chapter 5. Global Market Size and Forecast
5.1 By Product
5.2 By Technology
5.3 By Indication
5.4 By Manufacturing Type
5.5 By ROA
5.6 By Region

Chapter 6. Europe Market Size and Forecast
6.1 By Product
6.2 By Technology
6.3 By Indication
6.4 By Manufacturing Type
6.5 By ROA
6.6 By Country

Chapter 7. APAC Market Size and Forecast
7.1 By Product
7.2 By Technology
7.3 By Indication
7.4 By Manufacturing Type
7.5 By ROA
7.6 By Country

Chapter 8. North America Market Size and Forecast
8.1 By Product
8.2 By Technology
8.3 By Indication
8.4 By Manufacturing Type
8.5 By ROA
8.6 By Country

Chapter 9. LATAM Market Size and Forecast
9.1 By Product
9.2 By Technology
9.3 By Indication
9.4 By Manufacturing Type
9.5 By ROA
9.6 By Country

Chapter 10. MEA Market Size and Forecast
10.1 By Product
10.2 By Technology
10.3 By Indication
10.4 By Manufacturing Type
10.5 By ROA
10.6 By Country

Chapter 11. Competitive Landscape
11.1 Benchmarking of Key Players Based on Indication
11.2 Global Strategic Development of Key Players

Chapter 12. Company Profiles
12.1 AMEGA Biotech
12.2 Samsung Bioepis Co. Ltd.
12.3 Coherus BioSciences Inc.
12.4 Synthon Holding B.V.
12.5 BIOCAD
12.6 Zydus Cadila
12.7 Celltrion Inc.
12.8 Dr. Reddy's Laboratories Ltd.
12.9 Teva Pharmaceutical Industries Limited
12.10 Novartis AG
12.11 Pfizer Inc.
12.12 Mylan N.V.

For more information about this report visit https://www.researchandmarkets.com/r/7p8csv

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.